Metalloenzyme inhibitors for the treatment of Gram-negative bacterial infections: A patent review (2009-2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 7, 2013, Pages 777-788

  Supuran, Claudiu T ^a   Carta, Fabrizio ^a   Scozzafava, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Gram negative bacteria; HDH; LpxC; MBL; Metalloenzymes; PDF

Indexed keywords

ACTINONIN; ALKALINE PROTEINASE; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; CARBONATE DEHYDRATASE; CEPHALOSPORIN DERIVATIVE; ELASTASE; HISTIDINE DERIVATIVE; HISTIDINOL DEHYDROGENASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; METALLOPROTEINASE INHIBITOR; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; UDP (3 O(3-HYDROXYMYRISTOYL))N ACETYLGLUCOSAMINE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BIOSYNTHESIS; BRUCELLA SUIS; BURKHOLDERIA PSEUDOMALLEI; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LEGIONELLA PNEUMOPHILA; MYCOBACTERIUM TUBERCULOSIS; OXIDATION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; SALMONELLA TYPHIMURIUM; VIBRIO CHOLERAE; VIBRIO VULNIFICUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DESIGN; ENZYME INHIBITORS; ENZYMES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC;

EID: 84879359476     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.777042     Document Type: Review

References (95)

1. Raetz CRH. Molecular genetics of membrane phospholipid synthesis. Annu Rev Genet 1986;20:253-95
2. Wyckoff TJO, Raetz CRH, Jackman JE. Antibacterial and anti-inflammatory agents that target endotoxin. Trends Microbiol 1998;6:154-9 (Pubitemid 28202433)
3. Raetz CRH. Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal aq: transduction. J Bacteriol 1993;175:5745-53 (Pubitemid 23277419)
4. Xilinas ME. Method for treating drug-resistant bacteria and other infections with clioquinol, phanquinone, and related compounds. WO140215; 2009
5. Kappers J, Hearn JM, Qui R. Therapeutic compositions and methods for treating gram-negative bacterial infections. US0038917; 2011
6. White JR, Margolis PS, Trias J, Yuan Z. Targeting metalloenzymes: a strategy that works. Curr Opin Pharmacol 2003;3:502-7 (Pubitemid 37221130)
7. Adams E. The enzymatic synthesis of histidine from histidinol. J Biol Chem 1954;209:829-46
8. Gorish H, Holke W. Binding of histidinal to histidinol dehydrogenase. Eur J Biochem 1985;150:305-8
9. Gorish H. Steady-state investigations of the mechanism of histidinol dehydrogenase. Biochem J 1979;181:153-7
10. Parish T. Starvation survival response of Mycobacterium tuberculosis. J Bacteriol 2003;185:6702-6 (Pubitemid 37385891)
11. Fields PI, Swanson RW, Haidaris CG, Heffron F. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci USA 1986;83:5189-93 (Pubitemid 16051340)
12. Pilatz S, Breitbach K, Hein N, et al. Identification of burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Infect Immun 2006;74:3576-86 (Pubitemid 43794549)
13. Available from: http://www.cdc.gov/
14. Abdo M-R, Joseph P, Boigegrain R-A, et al. Brucella suis histidinol dehydrogenase: synthesis and inhibition studies of a series of substituted benzylic ketones derived from histidine. Bioorg Med Chem 2007;15:4427-33 (Pubitemid 46777294)
15. Winum JY, Montero JL, Kohler S. Histidinol dehydrogenase inhibitors, and use thereof as medicaments. US0129907; 2012
16. Kohler S, Foulongne V, Ouahrani-Bettache S, et al. Nonlinear partial differential equations and applications: the analysis of the intramacrophagic virulome of Brucella suis deciphers the environment encountered by the pathogen inside the macrophage host cell. Proc Natl Acad Sci USA 2002;99:15711-16 (Pubitemid 35407486)
17. Black TM, Hodgson JE, Knowles DJC, et al. Novel histidinol dehydrogenase. US0064848; 2002
18. Tanzer M, Shuster J R, Hamer L, et al. Methods for the identification of inhibitors of histidinol dehydrogenase as antibiotics. WO089156; 2005
19. Whittington D A, Rusche K M, Shin H, et al. Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc Natl Acad Sci USA 2003;100:8146-50 (Pubitemid 36842513)
20. Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev 1985;49:1-32 (Pubitemid 15134118)
21. Anderson MS, Bulawa CE, Raetz CRH. The biosynthesis of gram-negative endotoxin. Formation of lipid A precursors from UDP-GlcNAc in extracts of Escherichia coli. Biol Chem 1985;260:15536-41 (Pubitemid 16170091)
22. Beall B, Lutkenhaus J. Sequence analysis, transcriptional organization, and insertional mutagenesis of the envA gene of Escherichia coli. J Bacteriol 1987;169:5408-15 (Pubitemid 18017834)
23. Patchet AA, Nargund R, Chen M-H, Onishi H. Antibacterial agents. WO42179; 1997
24. Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agentsthat inhibit lipid A biosynthesis. Science 1996;274:980-2 (Pubitemid 26398419)
25. Anderson NH, Bowman J, Erwin A, et al. Antibacterial agents. WO062601; 2004
26. Patten PA, Armstrong ES. Combinations comprising a LpxC inhibitor and an antibiotic for use in the treatment of infections caused by gram negative bacteria. WO005355; 2011
27. Siddiqui MA, Mansoor UF, Reddy PA, Madison PS. Compounds for the treatment of inflamatory disorders and microbial diseases. WO064732; 2007
28. Takashima H, Yoshinaga M, Ushiki Y, et al. Novel hydroxamic acid derivatives. WO105515; 2008
29. Takashima H, Suga Y, Urabe H, et al. Novel hydroxamic acid derivatives having naphthyridine N-oxide. WO024356; 2010
30. Takashima H, Tsuruta R, Yabiuuchi T, et al. Novel hydroxamic acid derivative. WO132712; 2011
31. Reddy PAP, Mansoor UF, Siddiqui MA. Synthesis and use of antibacterial agents. US0212078; 2011
32. Mansoor UF, Reddy PAP, Siddiqui MA. Urea derivatives as antibacterial agents. US0212080; 2011
33. Brown MF, Che Y, Melnick MJ, et al. Fluoro-pyridinone derivatives usefuls as antibacterial agents. WO120397; 2012
34. Mansoor UF, Reddy PAP, Siddiqui MA. Hydantoin derivatives usefuls as antibacterial agents. WO027466; 2008
35. Clements JM, Coignard F, Johnson I, et al. Antibacterial activities and characterisation on novel inhibitors of LpxC. Antimicrob Agents Chemother 2002;46:1793-9 (Pubitemid 34535199)
36. Meinnel T, Blanquet S. Evidence that peptide deformylase and methionyltRNA( fMet) formyltransferase are encoded within the same operon in Escherichia coli. J Bacteriol 1993;175:7737-40 (Pubitemid 23346843)
37. Meinnel T, Blanquet S. Enzymatic properties of Escherichia coli peptide deformylase. J Bacteriol 1995;177:1883-7
38. Rajagopalan PTR, Yu C, Pei D. Peptide deformylase: a new type of mononuclear iron protein. J Am Chem Soc 1997;119:12418-19
39. Guilloteau J-P, Mathieu M, Giglione C, et al. The crystal structure of four peptide deformylase bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J Mol Biol 2002;320:951-62 (Pubitemid 34808817)
40. Serero A, Giglione C, Sardini A, et al. An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem 2003;278:52953-63 (Pubitemid 38035897)
41. Takeuchi N, Vial L, Panvert M, et al. Recognition of tRNAs by methionyl-tRNA transformylase from mammalian mitochondria. J Biol Chem 2001;276:20064-8
42. Djaballah H, AntezaK C. Benzofuran 4,5-diones as selective peptide deformylase inhibitors. US0071523; 2012
43. Frechette R, Davis S, Jaeger C, et al. Methods of use peptide deformylase inhibitors as novel antibacterial agents. WO38561; 2001
44. Sergeeva MV, Doppallapudi VR. Peptide deformylase activated prodrugs. WO089739; 2002
45. Meinnel T, Artaud I, Boularot A. Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same. WO077139; 2006
46. Thormann M. Peptide deformylase (PDF) inhibitors 3. WO131340; 2006
47. Thormann M. Imidazo (1,2a) pyridine derivatives as peptide deformylase (PDF) inhibitors. WO114261; 2006
48. Christensen SB IV, Cummings MD, Lee J, Xiang J-N. Peptide deformylase inhibitors. US0229341; 2006
49. Leber JD, Li M, Lee J, et al. Peptide deformylase inhibitors. US0052423; 2006
50. Axten JM, Medina JR. Peptide deformylase inhibitors. WO016364; 2007
51. Lee J. Peptide deformylase inhibitors. WO067904; 2007
52. Lee J. Peptide deformylase inhibitors. WO067906; 2007
53. Qin D, Norton B, Liao X, et al. Peptide deformylase inhibitors. WO061879; 2009
54. Aubart KM, Benowitz AB, Fang Y, et al. Peptide deformylase inhibitors. WO122450; 2012
55. Cali P, Hjelmencrantz A, Nauerum L. Isoxazoles as peptide deformylase inhibitors. US0043062; 2007
56. Hjelmencrantz A, Cali P, Groth T, et al. Benzimidazole derivatives and use thereof as peptide deformylase inhibitors. US0066672; 2007
57. Kang J-H, Yu S-W, Lee H-Y, et al. Novel hydroxamic acid derivative as peptide deformylase inhibitor and manifacturing method thereof. US0234333; 2008
58. Kang J-H, Yu S-W, Lee H-Y, et al. A new peptide deformylase inhibitor compound and manifacturing method thereof. US0168421; 2010
59. Pei D. Peptide deformylase inhibitors as novel antibiotics. US0203631; 2009
60. Hu W, Shi W, Ma H, et al. Peptide deformylase inhibitors containing 4-methylene pyrrolidine. WO000322; 2012
61. Hase CC, Filkenstein R. Bacterial extracellular zinc-containing metalloproteases. Microbiol Rev 1993;57:823-37
62. Supuran CT, Winum JY. Introduction to zinc enzymes as drug targets. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken; 2009. p. 3-12
63. Winum JY, Montero JL, Scozzafava A, Supuran CT. Zinc binding functions in the design of carbonic anhydrase inhibitors. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken; 2009. p. 39-72
64. Galloway DR. Pseudomonas aeruginosa elastase and elastolysis revisited: recent developments. Mol Microbiol 1991;5:2315-21 (Pubitemid 21895961)
65. Fukushima J, Yamamaoto S, Morihara K, et al. Structural gene and complete aminoacid sequence of Pseudomonas aeruginosa IFO 3455 elastase. J Bacteriol 1989;171:1698-04 (Pubitemid 19080811)
66. Chen DZ, Patel DV, Hackbarth CJ, et al. Actinonin, a natural occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 2000;39:1256-62 (Pubitemid 30090692)
67. Ramanatha-Girish S, McColm J, Clements JM, et al. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 2004;48:4835-42 (Pubitemid 39577691)
68. Leeds JA, Dean CR. Peptide deformylase as an antibacterial target: a critical assesment. Curr Opin Pharmacol 2006;8:8
69. Dowling JN, Saha AK, Glew RH. Virulence factors of the family Legionellaceae. Microbiol Rev 1992;56:32-60
70. Filkenstein RA, Filkenstein-Boesman M, Holt P. Vibrio cholerae hemagglutinin/lectin/protease hydrolyzes fibronectin and ovomucin: F. M. Burnet revisited. Proc Natl Acad Sci USA 1983;80:1092-5 (Pubitemid 13118092)
71. Del Prete S, Isik S, Vullo D, et al. DNA cloning, characterization and inhibition studies of an alpha-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae. J Med Chem 2012;55:10742-8
72. Miyoshi N, Miyoshi SI, Sugiyama K, et al. Activation of the plasma kallicrein-kinin system by Vibrio vulnificus protease. Infect Immun 1987;55:1936-9
73. Miyoshi S, Shinoda S. Role of the protease in the permeability enhancement by Vibrio vulnificus. Microbiol Immunol 1988;32:1025-32
74. Norqvist A, Norman B, Wolf-Watz H. Identification and charcterization of a zinc metalloprotease associated with invasion by the fish pathogen Vibrio anguillarum. Infect Immun 1990;58:3731-6 (Pubitemid 20353376)
75. Montecucco C. Green tea and polyphenol inhibitors of bacterial protease. WO105779; 2004
76. Appelbaum J. Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for their use thereof. WO084799; 2004
77. Bavari S, Gussio R, Burnett JC. Small molecule inhibitors of botulinum neurotoxins. US0086877; 2011
78. Bebrone C. Metallo-beta-lactamases (classification, activity genetic organisation, structure, zinc coordination) and their superfamily. Biochem Pharmacol 2007;74:1686-701
79. Crowder MW, Spencer J, Vila AJ. Metallo-beta-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc Chem Res 2006;39:721-8
80. Supuran CT, Scozzafava A, Clare BW. Bacterial protease inhibitors. Med Res Rev 2002;22:329-72 (Pubitemid 34620472)
81. Shoichet BK, Prati F. Nanomolar beta-lactamase inhibitors. US7928129; 2011
82. Dmitrienko GI, Johson WJ, Ramadhar TR, et al. Beta-lactamase inhibitors. US0046101; 2011
83. Maiti SM, Ling R, Yip J, et al. Novel fused bridged byciclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors. US0288063; 2011
84. Dmitrienko GI, Ghavami A, Goodfellow VJ, et al. Cephalosporine derivatives useful as beta-lactamase inhibitors and compositions and methods of use thereof. WO103686; 2011
85. Horton L, Palzkill T, Chen P, Song Y. Small molecle compounds as broad-spectrum inhibitors of metallo-beta-lactamases. WO088283; 2012
86. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168-81 (Pubitemid 351194064)
87. Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors. DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori: a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem 2006;49:2117-26
88. Nishimori I, Minakuchi T, Kohsaki T, et al. Carbonic anhydrase inhibitors. The beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett 2007;17:3585-94 (Pubitemid 46898819)
89. Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha-and beta-classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008;14:622-30 (Pubitemid 351736441)
90. Nishimori I, Takeuchi H, Supuran CT. Inhibition of beta-and alpha-CAs from Helicobacter pylori as potential novel gastric drugs. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Wiley, Hoboken; 2009. p. 359-74
91. Dean RC, Ryder NS. Methods for increasing susceptibility of peptide deformylase inhibitors by using efflux pump inhibitors. US0156645; 2009
92. Ammendola A, Wieber T, Wuzik A, Lang M. Inhibitors of biofilm formation of gram-positive and gram-negative bacteria. US0192192; 2009
93. Prince A, Tong L. Neuroamidase inhibitors and use thereof. WO054475; 2008
94. Opperman TJ, Williams JD, Peet NP, et al. Inhibitors of bacterial biofilm formation. WO142720; 2009
95. Lopez D, Hatton B, Kolter R. Inhibitors of biofilm formation. WO031964; 2011